Download MendeleyDiscovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.
Goodwin, N.C., Cianchetta, G., Burgoon, H.A., Healy, J., Mabon, R., Strobel, E.D., Allen, J., Wang, S., Hamman, B.D., Rawlins, D.B.(2015) ACS Med Chem Lett 6: 53-57
- PubMed: 25589930
- DOI: https://doi.org/10.1021/ml500242y
- Primary Citation of Related Structures:
4TPT - PubMed Abstract:
The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of other kinases. Enzymatic kinetic studies showed these molecules to be noncompetitive with ATP, suggesting allosteric inhibition. X-ray crystallography confirmed that these sulfonamides are a rare example of a type III kinase inhibitor that binds away from the highly conserved hinge region and instead resides in the hydrophobic pocket formed in the DFG-out conformation of the kinase, thus accounting for the high level of selectivity observed.
Organizational Affiliation:
Lexicon Pharmaceuticals , 350 Carter Road, Princeton, New Jersey 08540, United States.
